Publicaties
Gekozen filters:
Gekozen filters:
Use of lipid lowering therapy in primary care across Europe: results from the European study on cardiovascular risk prevention in daily practice (EURIKA) Universiteit Gent
New Strategies for the Development of Lipid Lowering Therapies to Reduce Cardiovascular Risk KU Leuven
The very high occurrence of cardiovascular events presents a major public health issue because treatment remains suboptimal. Lowering low-density lipoprotein cholesterol (LDL-C) with statins or ezetimibe in combination with a statin reduces major adverse cardiovascular events. The cardiovascular risk reduction in relation to the absolute LDL-C reduction is linear for most interventions without evidence of attenuation or increase in risk at low ...
Suboptimal lipid management in patients with acute ischemic stroke KU Leuven
OBJECTIVE: Lipid-lowering drugs are among the most widely used drugs in cardiovascular prevention. Statins are often abandoned due to side effects, or under dosed, leading to unreached LDL-cholesterol goals and increased occurrence of cardiovascular events. METHODS: We included hospitalized patients with an ischemic stroke or transient ischemic attack. Of 92 patients, low density lipoprotein cholesterol (LDL-C) levels and lipid lowering therapy ...
Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS). Vrije Universiteit Brussel
AIM:
A substantial number of cardiovascular events are not prevented by statin therapy, which is still regarded as the first-line therapy for hyperlipidaemia. Insights into the prevalence of lipid abnormalities of statin-treated patients in Belgium are lacking and may shed light on an unmet medical need for optimal use of current lipid-lowering therapies. This study aims to assess the prevalence and types of persistent lipid abnormalities ...
A substantial number of cardiovascular events are not prevented by statin therapy, which is still regarded as the first-line therapy for hyperlipidaemia. Insights into the prevalence of lipid abnormalities of statin-treated patients in Belgium are lacking and may shed light on an unmet medical need for optimal use of current lipid-lowering therapies. This study aims to assess the prevalence and types of persistent lipid abnormalities ...
A retrospective study of people with familial hypercholesterolaemia in a Belgian lipid clinic KU Leuven
BACKGROUND: Familial hypercholesterolaemia (FH) is a genetic disease characterised by hypercholesterolaemia and premature cardiovascular events. Early diagnosis and treatment can reduce the cardiovascular burden. We describe the characteristics of patients with heterozygous FH followed in a tertiary hospital in Belgium. METHODS: We retrospectively studied a population of 321 patients with definite heterozygous FH who visited the UZ Leuven lipid ...
Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS) KU Leuven
A substantial number of cardiovascular events are not prevented by statin therapy, which is still regarded as the first-line therapy for hyperlipidaemia. Insights into the prevalence of lipid abnormalities of statin-treated patients in Belgium are lacking and may shed light on an unmet medical need for optimal use of current lipid-lowering therapies. This study aims to assess the prevalence and types of persistent lipid abnormalities in patients ...
Monocyte and Macrophage Lipid Accumulation Results in Down-Regulated Type-I Interferon Responses KU Leuven
Macrophages are critical components of atherosclerotic lesions and their pro- and anti-inflammatory responses influence atherogenesis. Type-I interferons (IFNs) are cytokines that play an essential role in antiviral responses and inflammatory activation and have been shown to promote atherosclerosis. Although the impact of type-I IFNs on macrophage foam cell formation is well-documented, the effect of lipid accumulation in monocytes and ...
Fluorescent labeling of DNA : strategies, pitfalls and necessity for fluorescence microscopy investigations of gene therapy Universiteit Gent
Gene therapy is a field of research in which a huge amount of effort has been spent over the last two decades. To succeed, a correct therapeutic gene needs to be delivered into the cytoplasm of a cell for mRNA and nucleus of a cell for plasmid DNA (pDNA). To protect the nucleic acids, viral vectors and non-viral carriers have been used. Due to the many barriers that are encountered in the delivery, the design and evaluation of especially the ...
Relation Between Previous Lipid-Lowering Therapy and Infaret Size (Creatine Kinase-MB Level) in Patients Presenting With Acute Myocardial Infarction KU Leuven
Animal experimental data have shown that lipid-lowering agents reduce myocardial infarct size. This association has not been well studied in humans. We compared infarct size in 10,548 patients in the GUSTO IIb and PURSUIT trials who were (n = 1,028) or were not (n = 9,520) on lipid-lowering therapy before an enrolling myocardial infarction (MI). Patients using lipid-lowering agents before their index MI had smaller infarcts than those who were ...